Signatures Recent News

Signature Communications lands brief to handle Botox rival - 25/02/2010
Dermatology firm Galderma has turned to Signature Communications to promote…

Basilea Brings in Signature Communications - 08/02/2010
Signature Communications has been brought in to support a medical education…

Sun Smart, Skin Aware - Communiqué - 27/11/2009
Thirty to forty years ago, sun awareness campaigns to convey skin damage did…

Signature Secures Scar Prevention Brief - 03/06/2009
Signature Healthcare Communications has been bought onboard by Cranage Healthcare…

Signature Healthcare Communications Handed Solaraze Brief - 08/04/2009
Almirall UK has appointed Signature Healthcare Communications as its UK medical…

Signature Healthcare Communications Secures Galderma Brief - 19/03/2009
Dermatology experts Galderma have appointed Signature Communications to spearhead…

Visit the full news archive

How else can you respond when a new client presents you with the challenge 'you have six weeks to plan the tactics and implement a national healthcare professional launch meeting for a new first in class drug'; than to pick up the reins and race off?

With mitigating factors including the client being admitted to hospital with pneumonia the week before launch, the marketing assistant struck down with a chest infection and the worst weather conditions for years, on the 5th and 6th February Targinact was finally launched in the UK.

The Napp Pharmaceuticals hosted symposium “Advancing the Field in Pain Management: Integrating Agonists and Antagonists” commenced on Thursday evening at the London IMAX, where over 400 healthcare professionals from across the UK were presented with the clinical research and a specially developed animation of Targinact’s mode of action.  The meeting continued on Friday with a series of presentations including ‘The Use of Opioids in the Management of Pain’ and ‘Chronic Pain Guidelines and Treatments’ from a panel of eminent speakers.